Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report published on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Separately, Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Stock Performance

ATOS opened at $0.70 on Wednesday. The company has a market capitalization of $89.93 million, a P/E ratio of -3.16 and a beta of 1.20. Atossa Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.31. The stock has a fifty day moving average of $0.79 and a 200-day moving average of $1.10.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts predict that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ATOS. Intech Investment Management LLC acquired a new position in Atossa Therapeutics in the 3rd quarter worth about $29,000. The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics in the third quarter valued at approximately $75,000. State Street Corp grew its holdings in Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after acquiring an additional 69,180 shares during the last quarter. XTX Topco Ltd increased its position in Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after acquiring an additional 24,951 shares during the period. Finally, Barclays PLC increased its position in Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after acquiring an additional 123,683 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.